

## **Pharmacy Consulting Overview**

New cancer treatments are entering the market at an unrelenting, accelerated pace. Since 2018 alone, the FDA approved 121 new cancer indications, including 49 novel cancer drug entities. The FDA has even launched a Real-Time Oncology Review (RTOR) program, which allows the FDA to review early drug data in advance of a formal application. Under this program, one oncology drug gained FDA approval within two weeks of the application filing.

The explosive growth of treatment options in oncology means that the stakes for patients, providers, and health plans have never been higher. Health plans have small windows to carefully evaluate the appropriateness of new therapies and make needed course corrections.

## **Work With An Expert**

Oncology Analytics' team of board-certified oncology PharmD's can help you successfully navigate the world of anti-cancer drugs. These experienced professionals can assist by delivering a highly focused set of oncology pharmacy resources, which keep health plans up to date on the rapidly changing cancer therapy landscape. Through this increased awareness, health plans can improve cancer care for their members and develop more cost-effective approaches to high-quality care.

## **Services We Offer**

Oncology Analytics has both deep experience and a robust repository of effective tools and methods to guide health plans through the rapidly changing oncology drug landscape successfully. We have identified several high-value areas for oncology pharmacy optimization, which include the following.

- Review and update existing Drug Policies
- Step Therapy advisement
- Identify oncology-related agents that should require prior authorization
- Strengthen Part D prior authorization criteria
- Present oncology criteria to Pharmacy and Therapeutics or similar committee
- Utilization Management strategy advice
- Formulary Management strategy advice
- Biosimilar strategy development
- Develop oncology educational training programs for internal staff
- Monthly review of new oncology drug approvals
- Quarterly review of anticipated oncology drug approvals



## **About Oncology Analytics**

Oncology Analytics is a leading data analytics and technology-enabled services company dedicated to helping health plans, providers, and patients with solutions that are purpose-built for oncology. Through an evidence-based, real-world analytics approach to utilization management, Oncology Analytics' prior authorization platform is used by physicians to support 5 million health plan members in the US and Puerto Rico and covers the full spectrum of therapeutics, across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care. The extensive treatment library is continuously updated with the latest evidence-based regimens, which provides the most current options for value-based care for every patient case. For more information, please visit www.oncologyanalytics.com.